Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34+ positive selection

Bone Marrow Transplantation

Volumn 27, Issue 9, 2001, Pages 983-988

  Moscardo F ^a   Sanz, G F ^a   de la Rubia, J ^a   Jimenez C ^a   Saavedra, S ^a   Regadera, A ^a   Andreu, R ^a   Garcia I ^a   Plume G ^a   Martinez J ^a   Martin G ^a   Jarque, I ^a   Sanz, M A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Allogeneic hematopoietic stem cell transplantation; CD34+ selection; Hepatic veno occlusive disease

Indexed keywords

AMSACRINE; BUSULFAN; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; PREDNISOLONE; THIOTEPA;

ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL SELECTION; CONTROLLED STUDY; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD34; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0034986714     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703025     Document Type: Article

References (31)

1. The syndrome of hepatic veno-occlusive disease after marrow transplantation
2. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: Current status and novel approaches
3. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation
4. Veno-occlusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors
5. Veno-occlusive disease of the liver following bone marrow transplantation
6. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
7. Incidence and outcome of hepatic veno-occlusive disease after bone or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation
8. Risk factors for hepatic veno-occlusive disease following HLA-identical siblings bone marrow transplant for leukemia
9. Risk factors for hepatic veno-occlusive disease in 500 allogeneic bone marrow transplant recipients
10. Norethisterone treatment, a major risk factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation
11. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: Retrospective analysis of 137 cases at a single institution
12. + marrow cells in patients with breast cancer or neuroblastoma
13. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation
14. Increased serum levels of tumor necrosis α precede major complications of bone marrow transplantation
15. Rapid analysis of tumor necrosis factor-alpha mRNA expression during veno-occlusive disease of the liver after allogeneic bone marrow transplantation
16. Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation
17. 'Silent' presentation of veno-occlusive disease of the liver after liver transplantation as part of the process of cellular rejection with endothelial predilection
18. Allogeneic blood and bone marrow stem cell transplantation in haematological malignant diseases: A randomised trial
19. A prospective, randomized trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies
20. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
21. Allogeneic blood stem cells transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
22. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cells transplantation in patients with early leukemia: First results of a randomised multicentre trial of the European Group for Marrow Transplantation
23. Allogeneic blood cell transplants for haematological malignancy: Preliminary comparison of outcomes with bone marrow transplantation
24. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver
25. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide
26. Pathophysiology of the thrombophylic state in the cancer patient
27. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelials markers
28. Parameters of the fibrinolytic system in patients undergoing BMT: Elevation of PAI-1 in veno-occlusive disease
29. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant
30. Naturally occurring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of veno-occlusive disease of the liver